Halofuginol Derivatives for Reduced Toxicity and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds like halofuginone exhibit toxicity and stability issues, limiting their effectiveness in treating chronic inflammatory diseases, autoimmune diseases, and other conditions, while there is a need for compounds with improved biological activities and reduced toxicity.
Innovation Solution
Development of halofuginol and related compounds with specific structural formulas that inhibit tRNA synthetase, particularly glutamyl-prolyl tRNA synthetase, to treat various diseases by mimicking amino acid starvation, thereby reducing toxicity and improving stability and potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If halofuginone is used to treat diseases, then biological activity is achieved, but toxicity increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of halofuginone through systematic variation of substituents at positions R1-R6, including different halogen atoms (F, Cl, Br, I), alkyl groups, aryl groups, and heteroaryl groups. These structural parameter changes produce derivatives with altered biological activity and toxicity profiles, allowing optimization of the therapeutic index.
Solution Approach 2:
The patent applies local quality by introducing different functional groups at specific positions (R1-R6) of the halofuginone core structure. Each substituent position can be independently modified with different chemical groups to locally alter the molecule's properties, thereby achieving selective improvement of biological activity while reducing toxicity at specific molecular interaction sites.
2Reliability
If halofuginone is used to treat diseases, then biological activity is achieved, but stability decreases
Solution Approach 1:
The patent applies parameter changes by modifying chemical parameters such as substituent types (halogen, alkyl, aryl, heteroaryl), substituent positions, and molecular weight through systematic structural variations. These parameter changes enhance the stability of the compound while preserving or improving biological activity, addressing the instability issue of parent halofuginone.
3Object-affected harmful factors
If halofuginone derivatives are developed to reduce toxicity, then toxicity decreases, but biological activity may be reduced
Solution Approach 1:
The patent applies parameter changes by systematically varying substituent parameters (type, position, size) to find the optimal balance between reduced toxicity and maintained biological activity. The patent specifically identifies derivatives with substituents that reduce toxic side effects while preserving the core anti-inflammatory and immunosuppressive activities through careful parameter optimization.
Solution Approach 2:
The patent applies local quality by making targeted modifications at specific substituent positions (particularly R1-R4) to locally reduce toxicity without affecting the pharmacophore regions responsible for biological activity. This allows selective reduction of harmful effects while maintaining therapeutic benefits.
Data Source
AI summary
The present invention provides halofuginol, and derivatives and salts thereof, including diasteromerically enriched compositions thereof. The invention also provides pharmaceutical and cosmetic compositions thereof as well as methods for using halofuginol and derivatives thereof in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, malaria, ischemic damage, transplant rejection, neurodegenerative diseases, T-cell neoplasms, and cosmetic conditions.